EMA has provided additional advice on blood clots or low blood platelets occurring after vaccination with Vaxzevria (formerly COVID-19 Vaccine AstraZeneca).
EMA’s human medicines committee (CHMP) is recommending that healthcare professionals:
- must not give Vaxzevria to anyone who has had blood clots with low blood platelets (thrombosis with thrombocytopenia syndrome, TTS) after receiving the vaccine.
- should check for signs of blood clots in any person who has low blood platelets within 3 weeks of vaccination.
- should check for signs of low blood platelets in any person who has blood clots within 3 weeks of vaccination.
- should ensure that patients who have blood clots with low blood platelets after vaccination receive specialist care.
While blood clots with low blood platelets following vaccination are very rare, EMA continues to advise people to be aware of symptoms (see below), so they can receive prompt specialised medical treatment if needed.
The updated EMA recommendations for healthcare professionals are available in the vaccine’s product information. As for all vaccines, EMA and national authorities continuously monitor the safety of Vaxzevria and will update recommendations when necessary to protect public health.